Ovarian Seromucinous Carcinoma
Associated Genetic Biomarkers
NCI Definition: A malignant mixed epithelial neoplasm that arises from the ovary and is composed predominantly of serous and endocervical-type mucinous epithelium. 
Ovarian seromucinous carcinomas most frequently harbor alterations in KRAS, TP53, SRSF2, PIK3CA, and CDKN2A .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, TP53 Mutation, and PIK3CA Mutation are the most common alterations in ovarian seromucinous carcinoma .
There are 3 clinical trials for ovarian seromucinous carcinoma, of which 3 are open and 0 are completed or closed. Of the trials that contain ovarian seromucinous carcinoma as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open).
BRCA1 and BRCA2 are the most frequent gene inclusion criteria for ovarian seromucinous carcinoma clinical trials .
Bay2287411, carboplatin, and oncolytic measles virus encoding thyroidal sodium iodide symporter are the most common interventions in ovarian seromucinous carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.